1
|
Kong F, Hu C, Machtay M, Matuszak M, Xiao Y, Ten Haken R, Hirsh V, Pryma D, Siegel B, Gelblum D, Hayman J, Robinson C, Loo B, Videtic G, Faria S, Ferguson C, Dunlap N, Kundapu V, Paulus R, Curran W, Bradley J. OA02.04 Randomized Phase Ⅱ Trial (RTOG1106) on Midtreatment PET/CT Guided Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
2
|
Alexander E, Mick R, Pantel A, Katona B, Metz D, Pryma D, Soulen M. Abstract No. 708 Short-term toxicity of peptide receptor radionuclide therapy in patients with neuroendocrine tumors treated with prior transarterial liver-directed therapy. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
3
|
McDonald ES, Carlin S, Maxwell KN, Nayak A, Doot RK, Pantel AR, Farwell MD, Pryma DA, Clark AS, Shah P, DeMichele AM, Ziober A, Schubert EK, Palmer K, Lee HS, Matro J, de la Cruz L, Tchou J, Anderson DN, Feldman MD, Sheffer RE, Knollman H, Schnall MD, Makvandi M, Domchek S, Hubbard RA, Mach RH, Mankoff DA. Abstract PD4-07: PET imaging of PARP-1 expression in breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd4-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
18F-FluorThanatrace ([18F]-FTT) is a novel radiotracer shown to quantify Poly [ADP-ribose] polymerase 1 (PARP-1) expression in vitro and in vivo through a receptor-ligand interaction. A recent study at the University of Pennsylvania in women with ovarian cancer demonstrated in vivo visualization of PARP-1 expression in tumors using this radiotracer that closely correlated with an in vitro assay of PARP-1 in tumor tissue (Makvandi, M. J. Clin. Invest. 128:2116, 2018). A radioligand with PARP-1 specificity, [125I]-KX1, was also developed as a companion tool for ex vivo evaluation of PARP-1 expression and PARP inhibitor (PARPi) drug occupancy by radioligand binding assay (Makvandi, M. Cancer Res. 76:4516, 2016). As the first step in validating this biomarker in breast cancer, we performed a prospective clinical trial comparing in vivo [18F]-FTTuptake and ex vivo PARP-1 expression in women with primary breast cancer.
Methods: 24 patients with Stage I-IV primary breast cancer were imaged with [18F]-FTT prior to any therapy including surgery. We correlated in vivo uptake with ex vivo immunohistochemistry (IHC) for PARP-1 and [125I]-KX1 autoradiography in untreated surgical specimens. Tumors were analyzed for alterations in DNA repair genes, copy number-based as well as mutational signatures indicative of homologous recombination deficiency (HRD) and mutational burden, using our established protocol (Maxwell, KN, Nature Commun. 8:319, 2017).
Results: [18F]-FTT uptake was visualized above background in all primary breast tumors and known metastases. Two areas of unexpected uptake revealed an unknown contralateral breast cancer and an ovarian carcinoid, respectively. We expected that uptake might be highest in triple negative breast cancer (TNBC), where PARPi have been most heavily studied. However, a range of tracer uptake was observed in tumors independent of breast cancer subtype (hormone receptor positive/HER2 negative, TNBC, HER2+) and BRCA status. Uptake ratios (SUVmax tumor/SUV max opposite breast) ranged from 1.2-10.5 with a median 4.0. Ex vivo[125I]-KX1 autoradiography was performed on a subset of untreated primary tumors (n=5) and compared with IHC staining for PARP-1 on sequential sections. This revealed a close spatial correspondence between elevated PARP-1 expression by IHC and regions of elevated [125I]-KX1 binding radiographically. There was also a strong positive correlation between in vivo [18F]-FTT uptake and ex vivo quantitative [125I]-KX1 autoradiography (r=0.78). Genomic analysis of HRD in all tumors is pending and will be reported.
Conclusion: Initial analyses support the ability of [18F]-FTT to visualize and measure PARP-1 expression in breast cancer. This is the first step toward developing an imaging companion diagnostic to help guide PARP inhibitor treatment in breast cancer. Ongoing studies are expanding upon these results, testing the extent to which expression of PARP-1 by [18F]-FTT can predict response to PARP inhibitors and measure target engagement during therapy.
Citation Format: McDonald ES, Carlin S, Maxwell KN, Nayak A, Doot RK, Pantel AR, Farwell MD, Pryma DA, Clark AS, Shah P, DeMichele AM, Ziober A, Schubert EK, Palmer K, Lee HS, Matro J, de la Cruz L, Tchou J, Anderson DN, Feldman MD, Sheffer RE, Knollman H, Schnall MD, Makvandi M, Domchek S, Hubbard RA, Mach RH, Mankoff DA. PET imaging of PARP-1 expression in breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD4-07.
Collapse
Affiliation(s)
- ES McDonald
- University of Pennsylvania, Philadelphia, PA
| | - S Carlin
- University of Pennsylvania, Philadelphia, PA
| | - KN Maxwell
- University of Pennsylvania, Philadelphia, PA
| | - A Nayak
- University of Pennsylvania, Philadelphia, PA
| | - RK Doot
- University of Pennsylvania, Philadelphia, PA
| | - AR Pantel
- University of Pennsylvania, Philadelphia, PA
| | - MD Farwell
- University of Pennsylvania, Philadelphia, PA
| | - DA Pryma
- University of Pennsylvania, Philadelphia, PA
| | - AS Clark
- University of Pennsylvania, Philadelphia, PA
| | - P Shah
- University of Pennsylvania, Philadelphia, PA
| | | | - A Ziober
- University of Pennsylvania, Philadelphia, PA
| | - EK Schubert
- University of Pennsylvania, Philadelphia, PA
| | - K Palmer
- University of Pennsylvania, Philadelphia, PA
| | - HS Lee
- University of Pennsylvania, Philadelphia, PA
| | - J Matro
- University of Pennsylvania, Philadelphia, PA
| | | | - J Tchou
- University of Pennsylvania, Philadelphia, PA
| | - DN Anderson
- University of Pennsylvania, Philadelphia, PA
| | - MD Feldman
- University of Pennsylvania, Philadelphia, PA
| | - RE Sheffer
- University of Pennsylvania, Philadelphia, PA
| | - H Knollman
- University of Pennsylvania, Philadelphia, PA
| | - MD Schnall
- University of Pennsylvania, Philadelphia, PA
| | - M Makvandi
- University of Pennsylvania, Philadelphia, PA
| | - S Domchek
- University of Pennsylvania, Philadelphia, PA
| | - RA Hubbard
- University of Pennsylvania, Philadelphia, PA
| | - RH Mach
- University of Pennsylvania, Philadelphia, PA
| | - DA Mankoff
- University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
4
|
Fishbein L, Ben-Maimon S, Keefe S, Cengel K, Pryma DA, Loaiza-Bonilla A, Fraker DL, Nathanson KL, Cohen DL. SDHB mutation carriers with malignant pheochromocytoma respond better to CVD. Endocr Relat Cancer 2017; 24:L51-L55. [PMID: 28566531 DOI: 10.1530/erc-17-0086] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Accepted: 05/31/2017] [Indexed: 11/08/2022]
Affiliation(s)
- L Fishbein
- Division of EndocrinologyMetabolism and Diabetes and Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado School of Medicine, University of Colorado Cancer Center, Aurora, Colorado, USA
| | - S Ben-Maimon
- Department of MedicinePerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Renal and Hypertension DivisionPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - S Keefe
- Department of MedicinePerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Division of Medical Oncology and HematologyPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - K Cengel
- Department of Radiation OncologyPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - D A Pryma
- Department of RadiologyPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Division of Nuclear MedicinePerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - A Loaiza-Bonilla
- Department of MedicinePerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Division of Medical Oncology and HematologyPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - D L Fraker
- Department of SurgeryPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Division of Endocrine Oncologic SurgeryPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - K L Nathanson
- Department of MedicinePerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Division of Translational Medicine and Human GeneticsPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Abramson Cancer CenterUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - D L Cohen
- Department of MedicinePerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Renal and Hypertension DivisionPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| |
Collapse
|
5
|
Nayate AP, Dubroff JG, Schmitt JE, Nasrallah I, Kishore R, Mankoff D, Pryma DA. Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation. AJNR Am J Neuroradiol 2015; 36:1237-44. [PMID: 25767185 DOI: 10.3174/ajnr.a4281] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Accepted: 01/12/2015] [Indexed: 12/18/2022]
Abstract
BACKGROUND AND PURPOSE Fluorine-18 florbetapir is a recently developed β-amyloid plaque positron-emission tomography imaging agent with high sensitivity, specificity, and accuracy in the detection of moderate-to-frequent cerebral cortical β-amyloid plaque. However, the FDA has expressed concerns about the consistency of interpretation of [(18)F] florbetapir PET brain scans. We hypothesized that incorporating automated cerebral-to-whole-cerebellar standardized uptake value ratios into [(18)F] florbetapir PET brain scan interpretation would reduce this interreader variability. MATERIALS AND METHODS This randomized, blinded-reader study used previously acquired [(18)F] florbetapir scans from 30 anonymized patients who were enrolled in the Alzheimer's Disease Neuroimaging Initiative 2. In 4 separate, blinded-reading sessions, 5 readers classified 30 cases as positive or negative for significant β-amyloid deposition either qualitatively alone or qualitatively with additional adjunct software that determined standardized uptake value ratios. A κ coefficient was used to calculate interreader agreement with and without the use of standardized uptake value ratios. RESULTS There was complete interreader agreement on 20/30 cases of [(18)F] florbetapir PET brain scans by using qualitative interpretation and on 27/30 scans interpreted with the adjunct use of standardized uptake value ratios. The κ coefficient for the studies read with standardized uptake value ratios (0.92) was significantly higher compared with the qualitatively read studies (0.69, P = .006). CONCLUSIONS Use of standardized uptake value ratios improves interreader agreement in the interpretation of [(18)F] florbetapir images.
Collapse
Affiliation(s)
- A P Nayate
- From the Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - J G Dubroff
- From the Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - J E Schmitt
- From the Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - I Nasrallah
- From the Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - R Kishore
- From the Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - D Mankoff
- From the Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - D A Pryma
- From the Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania.
| | | |
Collapse
|
6
|
Batra V, Chacko AM, Gagliardi M, Hou C, Mikitsh JL, Freifelder RH, Kachur A, LeGeyt BC, Schmitz A, Toto L, Vaidyanathan G, Zalutsky MR, Matthay KK, Weiss WA, Gustafson WC, Pryma D, Maris JM. Abstract B48: Preclinical development of meta-[211At] astatobenzylguanidine ([211At] MABG) targeted radiotherapy for neuroblastoma. Cancer Res 2014. [DOI: 10.1158/1538-7445.pedcan-b48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neuroblastoma (NB) is a radiosensitive malignancy accounting for 10% of childhood cancer mortality. NB cells frequently express the norepinephrine transporter (NET) providing a specific mechanism for uptake of NET-ligands. Meta-[131I]iodobenzylguanidine ([131I]MIBG) is a NET-ligand radiotherapeutic that shows single-agent response rates in refractory NB of 40-50%. However, due to the long path lengths of 131 I beta (β)-emission, and low biological effectiveness compared to alpha (α)-emitting radionuclides, [131I]MIBG is generally not curative, perhaps due to non-targeting of isolated circulating tumor cells. Here we report our efforts to optimize NET-targeted radiotherapy by developing relevant preclinical models of refractory NB for α-particle therapeutic [211At] MABG therapy.
Methods: We first determined NET (SLC6A2) mRNA and protein expression in 35 human NB cell lines using quantitative RT-PCR and western blotting. We then chose 5 lines with absent to intermediate levels of native NET expression (NB1691, SKNSH, IMR5, NLF and SKNBE2) for dual forced overexpression of human NET and luciferase cDNAs. We used [125I]MIBG for cell-based uptake assays in all isogenic pairs and biodistribution experiments in athymic mice bearing three separate NET-transduced xenografts (N=5 per cell line). These cell lines were also treated with [131I]MIBG and/or external beam radiation (XRT) followed by multi-log cytotoxicity assays. Therapeutic trials of [131I]MIBG (25 mCi/kg) in NB1691 subcutaneous xenograft and metastatic mouse models were also conducted. In parallel, [211At] MABG was synthesized by: (i) cyclotron-production of 211 At via 209 Bi(α,2n)211At reaction (ii) distillation of 211 At from the target, and (iii) solid phase no-carrier-added synthesis of [211At] MABG by radioastato-destannylation. [211At] MABG uptake studies were performed in isogenic NB cell lines.
Results: Unlike primary human NBs, NET expression was low in the majority of 35 cell-lines studied (median normalized expression value = 0.145; range 0.000-1.005), but all transduced lines showed significant overexpression (0.860-1.107) comparable to human primary tumors. Transduced lines showed 4-10 fold higher uptake of [125I]MIBG than non-transduced isogenic parental cell lines in vitro, and demonstrated significant tumor-specific uptake and retention in vivo with tumor-muscle ratios ranging from 13.80 to 29.48. In vitro cytotoxicity experiments using [131I]MIBG showed NET-expressing cell lines to be more susceptible to treatment compared to non-NET expressing pairs (IC50 of 2.937nCi vs. 15.99 nCi). Treatment of mice bearing NB1691-NET xenografts with [131I]MIBG showed tumor growth delay (p=0.0065), but no significant impact on survival, likely due to de novo radioresistance (1200 cGy of XRT had no impact on NB1691 proliferation; IMR-05 showed 97% decreased cell viability). Lastly, we successfully synthesized [211At] MABG, with radiochemical yields of ∼20% and showed NET specific uptake of [211At] MABG into 1691 NET transfected cells.
Conclusions: Development of targeted radiotherapy for neuroblastoma has been limited by the lack of preclinical models and alternative therapeutics. Our development of multiple isogenic pairs with varying NET expression, documentation of de novo radiation sensitivity, and the production of [211At] MABG, will allow for rapid assessment of targeted radiotherapeutic strategies (including combination approaches) to support clinical development of alpha-particle therapeutics in a childhood cancer.
Citation Format: V Batra, AM Chacko, M Gagliardi, C Hou, J L. Mikitsh, R H. Freifelder, A Kachur, B C. LeGeyt, A Schmitz, L Toto, G Vaidyanathan, M R. Zalutsky, K K. Matthay, W A. Weiss, W C. Gustafson, D Pryma, J M. Maris. Preclinical development of meta-[211At] astatobenzylguanidine ([211At] MABG) targeted radiotherapy for neuroblastoma. [abstract]. In: Proceedings of the AACR Special Conference on Pediatric Cancer at the Crossroads: Translating Discovery into Improved Outcomes; Nov 3-6, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;74(20 Suppl):Abstract nr B48.
Collapse
Affiliation(s)
- V Batra
- 1The Children's Hospital of Philadelphia, Philadelphia, PA,
| | - AM Chacko
- 2University of Pennsylvania, Philadelphia, PA,
| | - M Gagliardi
- 1The Children's Hospital of Philadelphia, Philadelphia, PA,
| | - C Hou
- 2University of Pennsylvania, Philadelphia, PA,
| | | | | | - A Kachur
- 2University of Pennsylvania, Philadelphia, PA,
| | - B C. LeGeyt
- 2University of Pennsylvania, Philadelphia, PA,
| | - A Schmitz
- 2University of Pennsylvania, Philadelphia, PA,
| | - L Toto
- 2University of Pennsylvania, Philadelphia, PA,
| | | | | | - K K. Matthay
- 4University of California, San Francisco, San Francisco, CA
| | - W A. Weiss
- 4University of California, San Francisco, San Francisco, CA
| | - W C. Gustafson
- 4University of California, San Francisco, San Francisco, CA
| | - D Pryma
- 2University of Pennsylvania, Philadelphia, PA,
| | - J M. Maris
- 1The Children's Hospital of Philadelphia, Philadelphia, PA,
| |
Collapse
|
7
|
Cengel K, Lauren F, Alonso-Basanta M, Pryma D, Simone C, Findlay J. External Beam Radiation Therapy With or Without 131I-MIBG Systemic Radiation Therapy in the Therapy of Patients With Malignant Pheochromocytoma and Paraganglioma. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
Affiliation(s)
- L L Lin
- University of Pennsylvania, Philadelphia, PA
| | - D Pryma
- University of Pennsylvania, Philadelphia, PA
| | - C Koch
- University of Pennsylvania, Philadelphia, PA
| | - S Evans
- University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
9
|
Rengan R, Mick R, Pryma D, Lin L, Maity A, Gupta A, Evans T, Stevenson J, Langer C, Hahn S. A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy (CT-RT) for Stage IIIA/IIIB NSCLC: A Report of Toxicities and Metabolic Response. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
10
|
Groome JR, Pryma D, Donahue RM. Distribution and partial characterization of CREB-like immunoreactivity in the medicinal leech Hirudo. Invert Neurosci 2001; 4:95-103. [PMID: 12488979 DOI: 10.1007/s101580100011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The presence and distribution of immunoreactivity to the cyclic AMP response element binding protein (CREB) were determined in the central nervous system (CNS) and in peripheral tissues of the medicinal leech Hirudo. Western blots revealed several CREB-immunoreactive (CREB-IR) bands including one whose molecular weight (43-44 kDa) was similar to mammalian CREB. The 43-44 kDa CREB-like protein was detected in nuclear extracts of the ventral nerve cord and was not observed following preincubation of the primary antiserum with the epitope sequence. CREB-like immunoreactivity was detected in extracts from each of six regions of the leech CNS, and in extracts from leech body wall musculature, crop, intestine, jaw musculature, pharynx, and salivary tissues. Whole mounts of leech ganglia revealed specific CREB-IR in a restricted population of neurons distributed throughout the leech CNS. Apparent homologues to a pair of CREB-IR dorsolateral neurons were observed in most ganglia along the ventral nerve cord. Several CREB-IR neurons exhibited segmental specificity. A number of neurons stained with an antiserum to the cyclic AMP response element modulator (CREM). These neurons showed no overlap in location with CREB-IR neurons, and this staining was not eliminated with a preabsorption control. Possible roles for a CREB-like protein in the leech are discussed.
Collapse
Affiliation(s)
- J R Groome
- Biology Department, Harvey Mudd College, 1250 North Dartmouth Avenue, Claremont, CA 91711 USA.
| | | | | |
Collapse
|